Carmélia Maria Noia Barreto

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial

Neeta Somaiah, Anthony P. Conley, Edwin R. Parra et al. · The Lancet Oncology · 2022 · 157 citations

Medicine, Oncology, Pharmacology +16

Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues

Edwin R. Parra, Jie Zhai, Auriole Tamegnon et al. · Scientific Reports · 2021 · 65 citations · Full text

Medicine, Oncology, Pathology +17

The immune landscape of undifferentiated pleomorphic sarcoma

Rossana Lazcano, Carmélia Maria Noia Barreto, Ruth Salazar et al. · Frontiers in Oncology · 2022 · 26 citations · Full text

Life Sciences, Immunology, Oncology +17

In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments

Pedro Nazareth Aguiar, Jacob J. Adashek, Felipe Roitberg et al. · Value in Health Regional Issues · 2019 · 21 citations

Pharmacy, Oncology, Pharmacoeconomics +16

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Pedro Nazareth Aguiar, Pui San Tan, Sarah Simko et al. · Einstein (São Paulo) · 2019 · 19 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17